SMLE endocrinology questions

This patient's lean body habitus, acute osmotic symptoms with weight loss, ketosis-prone presentation, and low C-peptide strongly suggest type 1 diabetes mellitus due to autoimmune beta-cell destruction. Positive GAD-65 (or islet cell, IA-2, or zinc transporter-8) autoantibodies confirm the autoimmune basis and distinguish type 1 from type 2 diabetes, which typically shows preserved or elevated C-peptide and is not usually ketosis-prone at this low body mass index. Elevated fasting insulin would be expected in insulin-resistant type 2 diabetes, not type 1. Hepatitis C and marked hypertriglyceridemia are associations of type 2 diabetes and metabolic disease, not relevant here.

• B. Elevated fasting insulin suggests insulin resistance, typical of type 2 diabetes, inconsistent with this patient's low C-peptide.
• C. Marked hypertriglyceridemia is associated with insulin resistance and metabolic syndrome, not autoimmune type 1 diabetes.
• D. Hepatitis C is associated with insulin resistance and type 2 diabetes, not the presentation described.

Using the IADPSG criteria adopted by SCFHS and most international bodies, gestational diabetes mellitus is diagnosed with a 75 g OGTT performed between 24 and 28 weeks of gestation if any one of the following is met: fasting ≥5.1 mmol/L, 1-hour ≥10.0 mmol/L, or 2-hour ≥8.5 mmol/L. This patient's 1-hour value of 10.2 mmol/L alone is diagnostic, even though her fasting and 2-hour values are also abnormal. Only one abnormal value on a single OGTT is required, unlike the two-step approach used in some other diseases or regions.

• B. A normal fasting glucose does not exclude gestational diabetes if another timed value is abnormal.
• C. A single abnormal OGTT value using IADPSG one-step criteria is sufficient; no confirmatory fasting test is needed.
• D. Repeating the test is unnecessary once diagnostic criteria are met on a properly timed OGTT.

Maturity-onset diabetes of the young (MODY) should be suspected in a young, non-obese patient with mild hyperglycemia, negative pancreatic autoantibodies, preserved C-peptide, and a strong multigenerational family history suggesting autosomal dominant inheritance, as seen across three generations here. Type 1 diabetes is excluded by negative autoantibodies and preserved C-peptide. Type 2 diabetes is less likely given the normal body mass index and the distinctive inheritance pattern. LADA typically presents in adults over 30 years with positive autoantibodies, which are absent here. Genetic testing (e.g., for HNF1A, GCK mutations) would confirm the diagnosis and guide management, as some MODY subtypes respond to sulfonylureas rather than insulin.

• A. LADA occurs in adults typically over 30 years and requires positive autoantibodies, which this patient lacks.
• B. Type 2 diabetes is less likely given the normal body mass index and strong autosomal dominant family pattern.
• D. Type 1 diabetes is unlikely given negative autoantibodies and preserved C-peptide.

This patient meets diagnostic criteria for diabetic ketoacidosis: plasma glucose above 11 mmol/L (though DKA can occur at lower glucose too), metabolic acidosis with pH <7.3 and bicarbonate <18 mmol/L, and positive ketones. The fever, productive cough, and focal crackles at the right lung base point to pneumonia as the infective precipitant, which is among the most common triggers of DKA by increasing counter-regulatory hormones and insulin resistance. There is no history or clinical evidence suggesting an insulin pump malfunction. Acute pancreatitis would typically present with epigastric pain radiating to the back and elevated lipase, not isolated to this clinical picture. Myocardial infarction is a possible but far less likely precipitant in an 18-year-old without cardiac risk factors or chest pain.

• A. Myocardial infarction is highly unlikely in an 18-year-old with no cardiac symptoms or risk factors.
• C. There is no stated history of pump use or malfunction; the clinical findings point directly to a respiratory infection.
• D. Acute pancreatitis is not suggested by the findings described, which localize to the chest rather than the abdomen with elevated enzymes.

This patient's presentation, marked hyperglycemia above 30 mmol/L, serum osmolality above 320 mOsm/kg, absent or minimal ketosis, and near-normal pH, is consistent with hyperosmolar hyperglycemic state (HHS), which is distinguished from DKA by preserved insulin secretion sufficient to prevent significant ketogenesis but not hyperglycemia. The initial priority in HHS is aggressive fluid resuscitation with isotonic saline to correct the severe volume deficit, which is typically much larger than in DKA, before or alongside starting insulin, because rapid insulin administration without adequate fluids can cause a precipitous fall in osmolality and vascular collapse. Insulin is still required but is usually started after initial fluid resuscitation or at a lower rate once fluids are running. Bicarbonate is not indicated since the patient does not have significant metabolic acidosis. Mannitol has no role in the management of HHS and would worsen the osmotic derangement.

• A. Mannitol has no therapeutic role in HHS and would exacerbate the hyperosmolar state.
• C. Bicarbonate is not indicated as the patient does not have significant acidosis (pH 7.33, bicarbonate 20 mmol/L).
• D. Insulin infusion is appropriate but fluid resuscitation takes priority first to avoid worsening hemodynamic and osmotic instability.

The combination of headache, altered consciousness, bradycardia, and hypertension (Cushing triad) during DKA treatment is classic for cerebral edema, a feared complication most common in children. It results from rapid shifts in osmolality when plasma glucose and effective osmolality fall too quickly relative to intracellular solutes in the brain, causing fluid to shift into brain cells. Risk is reduced by gradual correction of glucose and osmolality, avoiding overly aggressive fluid boluses, and careful neurological monitoring. Immediate management includes slowing fluid administration and giving mannitol or hypertonic saline.

• A. Hypokalemia causes tachyarrhythmias or flaccid weakness, not the bradycardia-hypertension-headache triad described.
• C. Meningitis would typically present with fever and neck stiffness and is not related temporally to DKA treatment in this pattern.
• D. Hypoglycemia would cause tachycardia and sweating, not bradycardia with hypertension, and does not explain the Cushing triad pattern.

In a conscious patient who can safely swallow, oral fast-acting carbohydrate (such as glucose tablets, juice, or regular soda) is the first-line treatment for hypoglycemia, with glucose rechecked in 15 minutes. Intramuscular glucagon and intravenous dextrose are reserved for patients who are unconscious, severely confused, or unable to swallow safely due to aspiration risk. Delaying treatment risks progression to seizures or loss of consciousness. This stepwise approach follows the standard rule of 15 used in diabetes emergency management.

• A. Glucagon injection is unnecessary and more invasive when the patient is conscious and can take oral carbohydrate safely.
• C. Intravenous access and dextrose are reserved for patients who cannot take oral intake, such as those unconscious or vomiting.
• D. Withholding treatment risks worsening neurological symptoms and is inappropriate when a conscious patient can be treated immediately.

Metformin works mainly by activating AMP-activated protein kinase, reducing hepatic gluconeogenesis and improving peripheral insulin sensitivity without stimulating insulin secretion, so it rarely causes hypoglycemia alone. It is renally cleared, and in advanced kidney disease (eGFR under 30 mL/min/1.73m²) it accumulates and increases the risk of lactic acidosis, a rare but potentially fatal complication. Current guidelines recommend avoiding metformin when eGFR falls below 30 mL/min/1.73m² and using caution with dose reduction between 30 and 45 mL/min/1.73m². This patient's eGFR of 25 mL/min/1.73m² falls below the safety threshold.

• A. Volume depletion from osmotic diuresis is characteristic of SGLT2 inhibitors, not metformin.
• C. Metformin is not hepatotoxic; its main renal risk relates to lactic acidosis, not liver clearance.
• D. Metformin does not cause significant hypoglycemia because it does not stimulate insulin secretion, regardless of renal function.

Sulfonylureas close the SUR1-linked ATP-sensitive potassium channel on pancreatic beta cells, causing depolarization and insulin release independent of ambient glucose levels. This glucose-independent stimulation of insulin secretion is the mechanism behind their characteristic adverse effects of hypoglycemia and weight gain, since insulin promotes both glucose uptake and fat storage. These risks are more pronounced in the elderly, in renal impairment, and with long-acting agents such as glibenclamide. This mechanism contrasts with agents like metformin or SGLT2 inhibitors that carry much lower hypoglycemia risk.

• A. Increased urinary glucose excretion describes SGLT2 inhibitors, which cause weight loss, not weight gain.
• C. Sulfonylureas do not primarily work by increasing insulin sensitivity; that is the mechanism of thiazolidinediones.
• D. Decreased intestinal glucose absorption describes alpha-glucosidase inhibitors, not sulfonylureas, and does not explain weight gain.

SGLT2 inhibitors block glucose reabsorption in the proximal tubule, lowering blood glucose independent of insulin and promoting a relative increase in glucagon-to-insulin ratio that favors ketogenesis. During physiological stress such as surgery, fasting, or infection, this can precipitate ketoacidosis with near-normal or only mildly elevated glucose levels, termed euglycemic DKA. Current guidelines recommend stopping SGLT2 inhibitors 3-4 days before elective surgery to prevent this complication. The diagnosis requires a high index of suspicion because the glucose level does not reflect the severity of the acidosis.

• B. Lactic acidosis is not a recognized effect of SGLT2 inhibitors; their main metabolic risk is euglycemic ketoacidosis.
• C. Starvation ketosis alone does not typically cause a pH as low as 7.22 with such a marked bicarbonate drop, and the medication and perioperative context are directly relevant.
• D. Pancreatitis can cause abdominal pain but does not typically explain ketonuria and this degree of metabolic acidosis in this context.

GLP-1 receptor agonists, such as liraglutide and semaglutide, enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety, leading to significant weight loss. Several agents in this class have shown reductions in major adverse cardiovascular events in high-risk patients with type 2 diabetes and established cardiovascular disease. These properties make them a preferred add-on choice in patients with obesity and atherosclerotic cardiovascular disease who need further glycemic control. Common adverse effects include nausea and vomiting, which usually improve with dose titration.

• A. Alpha-glucosidase inhibitors delay carbohydrate absorption in the gut but do not stimulate insulin secretion or provide proven cardiovascular benefit.
• C. Thiazolidinediones improve insulin sensitivity but cause weight gain and fluid retention, and are associated with increased heart failure risk.
• D. Sulfonylureas increase insulin secretion independent of glucose levels and cause weight gain, not weight loss, and lack proven cardiovascular benefit.

The 3 AM glucose of 48 mg/dL with nocturnal sweating and confusion, followed by rebound fasting hyperglycemia, confirms the Somogyi phenomenon, in which nocturnal hypoglycemia triggers counter-regulatory hormone release and rebound hyperglycemia. The correct response to documented nocturnal hypoglycemia is to reduce the evening intermediate-acting insulin (NPH) dose, not to increase morning insulin, which would worsen the hypoglycemia. This distinguishes it from the dawn phenomenon, where early morning glucose rises due to nocturnal growth hormone and cortisol surges without preceding hypoglycemia, and which is managed by increasing, not decreasing, evening insulin.

• B. Increasing the dinner NPH dose would worsen the nocturnal hypoglycemia that is driving the rebound hyperglycemia.
• C. Adding more insulin at bedtime would deepen the nocturnal hypoglycemia rather than correct it.
• D. Increasing morning rapid-acting insulin does not address the nocturnal hypoglycemia causing the rebound.

Current guidelines recommend annual screening for diabetic kidney disease starting at the time of diagnosis in type 2 diabetes using a spot urine albumin-to-creatinine ratio (UACR), because it is a sensitive, convenient, and reproducible marker of early glomerular damage. A UACR of 30-300 mg/g defines moderately increased albuminuria (previously called microalbuminuria), prompting further risk stratification and renoprotective therapy. Estimated glomerular filtration rate (eGFR) should be measured alongside UACR to stage chronic kidney disease. A 24-hour urine collection is cumbersome and not needed for routine screening.

• B. Cystatin C is used to refine eGFR estimation in specific situations, not as the first-line screening test for nephropathy.
• C. A 24-hour urine collection is cumbersome, prone to collection error, and not recommended for routine screening.
• D. Renal ultrasound is used to evaluate structural kidney disease, not to screen for early diabetic nephropathy.

In patients with diabetes and confirmed albuminuria (UACR greater than 30 mg/g), an ACE inhibitor or angiotensin receptor blocker is indicated regardless of blood pressure level, because these agents reduce intraglomerular pressure by dilating the efferent arteriole, lowering albuminuria and slowing progression to end-stage renal disease. This renoprotective effect is independent of their antihypertensive action. Serum potassium and creatinine should be monitored after initiation, and the drug should be avoided in pregnancy. Calcium channel blockers and thiazides lower blood pressure but lack this specific antiproteinuric effect.

• A. Thiazide diuretics lower blood pressure but do not provide the specific renoprotective, antiproteinuric effect of renin-angiotensin system blockade.
• B. Dihydropyridine calcium channel blockers do not reduce intraglomerular pressure and lack the specific antiproteinuric benefit of ACE inhibitors.
• C. Severe protein restriction is not recommended in diabetic nephropathy and may contribute to malnutrition without proven renal benefit.

Patients with type 2 diabetes should have an initial dilated eye examination at the time of diagnosis, because retinopathy may already be present given the often long preceding asymptomatic hyperglycemic period. If that first examination is normal, as in this patient, follow-up screening is recommended every 1 to 2 years, with annual screening being the standard interval used in most national programmes. Earlier or more frequent review is required if any retinopathy is detected or if risk factors such as poor glycemic control or pregnancy are present. Relying on visual symptoms alone is inappropriate because diabetic retinopathy is often asymptomatic until advanced, sight-threatening stages such as macular edema or proliferative disease develop.

• A. Retinopathy is often asymptomatic until advanced stages, so waiting for symptoms risks irreversible vision loss.
• B. A 1-month interval is unnecessarily frequent for a patient with a normal baseline examination and no risk factors.
• C. A 5-year interval is too long and would miss asymptomatic progression of retinopathy.

The Semmes-Weinstein 10 g monofilament test is performed by applying the filament perpendicular to the skin, typically at the plantar surface over the great toe and metatarsal heads, with enough pressure to cause it to bend or buckle, while the patient's eyes are closed so they cannot use visual cues to anticipate the stimulus. The patient reports whether and where they feel the touch. Loss of protective sensation on this test identifies patients at high risk for neuropathic foot ulceration and amputation. The test should not be performed with the patient watching, since this introduces visual anticipation and reduces sensitivity for detecting true sensory loss.

• A. Dragging the monofilament without bending it does not deliver the standardized 10 g force required for the test.
• C. The monofilament test assesses light touch at specific plantar sites, not tendon reflexes, which are assessed differently.
• D. Testing with eyes open allows visual anticipation of the touch, reducing the accuracy of the sensory assessment.

Patients with diabetic peripheral neuropathy have impaired protective sensation and are at high risk of unnoticed trauma leading to ulceration, so daily self-inspection of the entire foot, including the soles and between the toes, using a mirror if direct visualization is difficult, is a cornerstone of prevention. Early detection of blisters, cracks, or color changes allows prompt treatment before ulceration occurs. Patients should always wear well-fitting protective footwear, avoid extremes of temperature because thermal injury may go unnoticed, and have corns, calluses, and nails managed by a trained podiatrist rather than self-treating with sharp instruments.

• A. Hot water soaks risk unnoticed thermal burns because protective sensation is impaired.
• B. Walking barefoot increases the risk of unnoticed trauma and puncture injuries in a foot with impaired sensation.
• C. Self-trimming of corns and calluses with sharp instruments risks accidental cuts that can go unnoticed and progress to infection.

An elevated TSH together with a free T4 below the reference range defines overt primary hypothyroidism, reflecting failure of the thyroid gland with loss of negative feedback and compensatory pituitary TSH hypersecretion. In subclinical hypothyroidism, TSH is mildly elevated but free T4 remains within the normal range. Central hypothyroidism, caused by pituitary or hypothalamic disease, presents with a low or inappropriately normal TSH in the setting of a low free T4, not an elevated TSH. Sick euthyroid syndrome typically shows a low or normal TSH with variable T4 and low T3 in the setting of acute severe illness, which does not fit this clinical picture.

• A. Central hypothyroidism is characterized by a low or inappropriately normal TSH, not an elevated one.
• B. Subclinical hypothyroidism requires a normal free T4 with only an elevated TSH, which is not the case here.
• C. Sick euthyroid syndrome typically occurs in acutely ill patients and shows a low or normal TSH, not an elevated one.

Hashimoto thyroiditis is an autoimmune disease in which anti-thyroid peroxidase (anti-TPO) antibodies are present in over 90% of patients and are the most sensitive serologic marker confirming autoimmune etiology of hypothyroidism. The clinical picture of a firm, non-tender goiter with primary hypothyroidism (elevated TSH, low free T4) strongly suggests Hashimoto thyroiditis, and anti-TPO testing is the standard confirmatory test. Ultrasound may show heterogeneous echotexture but is not diagnostic of autoimmunity. Thyroglobulin is used mainly as a tumor marker after thyroidectomy for differentiated thyroid cancer, not for diagnosing autoimmune thyroiditis.

• A. Ultrasound can show a heterogeneous gland but does not confirm the autoimmune cause.
• C. Thyroglobulin is used for monitoring thyroid cancer recurrence, not diagnosing Hashimoto thyroiditis.
• D. Radioactive iodine uptake is used to evaluate hyperthyroidism, not hypothyroidism from Hashimoto thyroiditis.

The combination of diffuse goiter with bruit, thyrotoxicosis, and infiltrative ophthalmopathy (proptosis, lid retraction, periorbital edema) is characteristic of Graves disease, an autoimmune condition caused by stimulating antibodies against the TSH receptor. TSH-receptor antibodies (TRAb or TSI) are present in over 95% of patients with Graves disease and are the most specific confirmatory test, especially useful when the clinical picture is not fully classic or when distinguishing Graves disease from other causes of thyrotoxicosis. Calcitonin is a marker for medullary thyroid carcinoma, not Graves disease. ANA is relevant to lupus and other connective tissue diseases, not thyroid autoimmunity.

• A. Thyroglobulin is a tumor marker and does not confirm the autoimmune etiology of thyrotoxicosis.
• B. Calcitonin is elevated in medullary thyroid carcinoma, unrelated to Graves disease.
• C. ANA is used in the workup of systemic lupus erythematosus, not Graves disease.

In a woman of reproductive age with Graves disease who desires definitive treatment and plans to conceive, radioactive iodine (RAI) ablation is a standard first-line option, provided pregnancy is excluded before treatment and reliably avoided for 6 months afterward. RAI achieves permanent control without the surgical risks of thyroidectomy (recurrent laryngeal nerve injury, hypoparathyroidism) and avoids years of antithyroid drug therapy. Surgery is reserved for large compressive goiters, suspected malignancy, or patient preference against radioiodine. Beta-blockers only control adrenergic symptoms and do not treat the underlying hyperthyroidism.

• A. Beta-blockers control symptoms like tachycardia but do not treat the underlying thyrotoxicosis.
• B. Thyroidectomy is reserved for large goiters, suspected malignancy, or contraindications to radioiodine.
• D. Long-term antithyroid drugs have a high relapse rate and do not provide the definitive control she wants before conceiving.

Propylthiouracil (PTU) is preferred over methimazole during the first trimester because methimazole is associated with a rare embryopathy including aplasia cutis and choanal/esophageal atresia. However, PTU carries a distinct risk of severe hepatotoxicity, including fulminant liver failure, which is why it is limited to the first trimester and then switched back to methimazole after 16 weeks. Agranulocytosis can occur with both drugs, not exclusively one, so it does not distinguish them. Choanal atresia and aplasia cutis are methimazole-associated embryopathies, not seen with PTU, making them incorrect for the drug used in this scenario.

• B. Agranulocytosis is a risk with both propylthiouracil and methimazole, not unique to the first-trimester drug.
• C. Choanal atresia is part of the methimazole embryopathy syndrome, not a PTU adverse effect.
• D. Aplasia cutis is a methimazole-associated teratogenic effect, not an adverse effect of PTU.

Subacute (de Quervain) thyroiditis typically follows a viral upper respiratory illness and presents with a painful, tender goiter, systemic symptoms, and markedly elevated ESR. The transient thyrotoxic phase results from follicular disruption releasing preformed hormone, and the hallmark finding distinguishing it from Graves disease is a low radioactive iodine uptake despite elevated thyroid hormones. Hashimoto thyroiditis presents as a painless goiter with hypothyroidism, and Graves disease would show elevated, not reduced, iodine uptake. Acute suppurative thyroiditis presents with high fever, systemic toxicity, and often a fluctuant abscess, usually in immunocompromised patients.

• A. Hashimoto thyroiditis causes a painless goiter with hypothyroidism, not a tender, painful gland with thyrotoxicosis.
• B. Graves disease would show increased, not decreased, radioactive iodine uptake.
• D. Acute suppurative thyroiditis is typically associated with high fever, systemic sepsis, and a fluctuant mass, not a self-limited course.

The initial step in evaluating any palpable thyroid nodule is measuring serum TSH, as this determines the subsequent workup pathway. If TSH is low, a radionuclide scan is performed to check for an autonomously functioning ("hot") nodule, which rarely requires biopsy. If TSH is normal or elevated, thyroid ultrasound is the next step to characterize the nodule and decide on fine-needle aspiration based on sonographic risk features and size criteria. Proceeding directly to biopsy or ultrasound without first checking TSH skips the step that determines whether a functional cause needs to be excluded first.

• A. Ultrasound is appropriate but TSH must be checked first to guide the overall diagnostic pathway.
• B. Biopsy is guided by ultrasound findings and nodule size, which are determined only after checking TSH and imaging.
• D. A radionuclide scan is only indicated if TSH is found to be low, not as the first test.

Papillary thyroid carcinoma is the most common histologic type of thyroid cancer and typically carries an excellent prognosis, with 10-year survival rates exceeding 95% when treated appropriately with surgery (lobectomy or total thyroidectomy depending on size and risk factors) and selective use of radioactive iodine. The cytologic features described, papillary architecture, nuclear overlapping, and intranuclear inclusions ('Orphan Annie eye' nuclei), are classic for this tumor. Unlike anaplastic carcinoma, which is highly aggressive and rapidly fatal, papillary carcinoma usually has an indolent course even when lymph node metastases are present. Medullary thyroid carcinoma, arising from C cells, has a less favorable prognosis than papillary carcinoma, especially in advanced stages.

• A. Papillary thyroid carcinoma typically has an indolent course, and rapid distant metastasis within months is atypical.
• C. Transformation to anaplastic carcinoma is rare and not an expected feature of papillary thyroid carcinoma.
• D. Medullary thyroid carcinoma generally carries a worse prognosis than papillary thyroid carcinoma, which is not comparable here.

Dopamine agonists are first-line therapy for prolactinomas of any size because lactotroph cells are under tonic dopaminergic inhibition, and stimulating dopamine D2 receptors suppresses prolactin secretion and shrinks the tumor in most patients. Cabergoline is preferred over bromocriptine due to its higher efficacy, longer half-life, and better tolerability. Surgery is reserved for dopamine agonist resistance or intolerance, or for acute visual compromise. This patient has a microadenoma without mass effect, so medical therapy is appropriate and usually restores menstrual cycles and fertility.

• B. Surgery is reserved for cases resistant or intolerant to dopamine agonists, not as first-line therapy.
• C. Radiotherapy is a third-line option used when medical and surgical therapy fail or are contraindicated.
• D. Observation is inappropriate given significant hyperprolactinemia with symptomatic amenorrhea and galactorrhea requiring treatment.

Prolactin secretion is normally under continuous inhibitory control by hypothalamic dopamine acting on D2 receptors of pituitary lactotrophs. Metoclopramide is a dopamine D2 receptor antagonist, so it removes this tonic inhibition and causes drug-induced hyperprolactinemia, typically with prolactin levels below 100-150 ng/mL. This is a common cause of hyperprolactinemia and should be excluded before pursuing further pituitary workup, especially with a normal MRI. Stopping the offending drug, if feasible, resolves the hyperprolactinemia.

• B. A normal MRI makes a prolactin-secreting adenoma unlikely as the cause here.
• C. The patient's TSH and clinical picture do not indicate hypothyroidism, and this is not the given history.
• D. She has a negative pregnancy test, excluding a pregnancy-related mechanism.

In central (secondary) hypothyroidism, a low or inappropriately normal TSH occurs together with a low free T4, because the pituitary or hypothalamus fails to adequately stimulate the thyroid gland. This pattern contrasts with primary hypothyroidism, where TSH is elevated in response to low free T4. Her history of severe postpartum hemorrhage raises strong suspicion for Sheehan syndrome, postpartum pituitary infarction from hypotension, which can present years later with hypopituitarism. TSH alone is unreliable for diagnosing hypothyroidism when pituitary disease is suspected; free T4 and other pituitary axes should be assessed.

• A. In Hashimoto thyroiditis (primary hypothyroidism), TSH would be elevated, not low-normal, in response to low free T4.
• B. Subclinical hypothyroidism is defined by elevated TSH with normal free T4, which does not match this biochemical pattern.
• C. Thyroid hormone resistance typically shows elevated or normal TSH with elevated free T4, not a low free T4 with inappropriately low TSH.

The water deprivation test is the standard investigation to confirm diabetes insipidus and distinguish it from primary polydipsia. Fluids are withheld under supervision while serum and urine osmolality are serially measured; failure to concentrate urine despite rising serum osmolality supports diabetes insipidus. Desmopressin is then administered, and a subsequent rise in urine osmolality of more than 50% indicates central diabetes insipidus (due to ADH deficiency), whereas minimal response suggests nephrogenic diabetes insipidus. Direct measurement of plasma copeptin or ADH, where available, is an emerging alternative but the water deprivation test remains the classic approach.

• B. A single serum osmolality measurement cannot differentiate diabetes insipidus from primary polydipsia without the dynamic water deprivation protocol.
• C. Urinary free cortisol evaluates for Cushing syndrome, not polyuria from diabetes insipidus.
• D. Normal glucose has already been noted, excluding diabetes mellitus as the cause of polyuria.

During water deprivation, failure to concentrate urine despite a rising serum osmolality indicates diabetes insipidus rather than primary polydipsia. The subsequent robust increase in urine osmolality of more than 50% after desmopressin administration demonstrates that the renal tubules remain responsive to antidiuretic hormone, confirming that the deficiency lies in ADH secretion rather than renal action. This pattern is diagnostic of central diabetes insipidus, commonly caused by pituitary or hypothalamic lesions, trauma, or surgery, and it is treated with desmopressin replacement.

• A. In nephrogenic diabetes insipidus the kidneys are resistant to ADH, so urine osmolality would show minimal or no rise after desmopressin administration.
• B. SIADH presents with hyponatremia and concentrated urine at baseline, not dilute urine with a hypertonic serum osmolality.
• D. In primary polydipsia, urine osmolality typically rises appropriately during water deprivation itself, before desmopressin is given.

The combination of hypotonic hyponatremia with inappropriately concentrated urine (urine osmolality greater than 100 mOsm/kg), elevated urine sodium (>40 mmol/L), and clinical euvolemia in the absence of renal, adrenal, thyroid, or diuretic causes defines SIADH. The kidney fails to dilute urine despite low plasma osmolality because ADH secretion continues inappropriately. Common causes include CNS disease, pulmonary disease, and malignancy, and the diagnosis is one of exclusion after ruling out hypothyroidism and adrenal insufficiency.

• A. Diuretic use is excluded by history and would typically show volume depletion.
• B. Primary polydipsia causes dilute urine (low urine osmolality), not concentrated urine.
• D. Hypovolemic hyponatremia from GI loss would show low urine sodium (<20 mmol/L) and clinical signs of volume depletion.

Correction of chronic severe hyponatremia should not exceed 8 mmol/L in 24 hours (or roughly 4-6 mmol/L in the first few hours once symptoms resolve) because rapid overcorrection risks osmotic demyelination syndrome. A rise of 12 mmol/L in 6 hours has already exceeded safe limits, so hypertonic saline must be stopped and the rate reversed using free water (5% dextrose) with desmopressin to prevent further autonomous correction from ongoing water diuresis. This combination, sometimes called a 'relowering' strategy, is the recommended rescue approach.

• B. Continuing hypertonic saline would worsen the already excessive correction rate and increase osmotic demyelination risk.
• C. Oral salt tablets would further raise sodium and are inappropriate when correction has already exceeded safe limits.
• D. Hydrocortisone does not address overcorrection; it is used for adrenal insufficiency-related hyponatremia, which is not indicated here.

When clinical features suggest Cushing syndrome, the first step is to confirm the presence of hypercortisolism using one of the screening tests: overnight 1 mg low-dose dexamethasone suppression test, late-night salivary cortisol, or 24-hour urinary free cortisol. Failure of cortisol to suppress below 1.8 mcg/dL (50 nmol/L) after dexamethasone confirms autonomous cortisol production. Only after hypercortisolism is biochemically confirmed should further tests be used to determine the cause (ACTH-dependent versus independent).

• B. The high-dose dexamethasone suppression test is used to differentiate pituitary from ectopic ACTH-dependent Cushing syndrome, not to screen for the diagnosis.
• C. Plasma ACTH alone does not confirm the presence of hypercortisolism and is used later for localization once Cushing syndrome is established.
• D. Inferior petrosal sinus sampling is an invasive localization test used only when pituitary versus ectopic ACTH source remains unclear after initial workup.

An elevated ACTH confirms ACTH-dependent Cushing syndrome, which narrows the differential to a pituitary corticotroph adenoma (Cushing disease) or an ectopic ACTH-secreting tumor. Suppression of cortisol by more than 50% on high-dose dexamethasone indicates that the ACTH source retains partial feedback sensitivity to glucocorticoids, a feature typical of pituitary corticotroph adenomas rather than most ectopic sources. This pattern supports pituitary MRI as the next step to localize a corticotroph adenoma.

• A. An adrenal adenoma causes ACTH-independent Cushing syndrome, which would present with a suppressed, not elevated, ACTH level.
• B. Ectopic ACTH-secreting tumors typically fail to suppress with high-dose dexamethasone because they lack glucocorticoid feedback sensitivity.
• D. Primary bilateral adrenal hyperplasia causing Cushing syndrome is ACTH-independent and would show a suppressed ACTH level, not an elevated one.

Primary adrenal insufficiency (Addison disease) results from destruction of the adrenal cortex, causing deficiency of both cortisol and aldosterone. The loss of cortisol's negative feedback leads to markedly elevated ACTH, which also stimulates melanocytes causing hyperpigmentation of skin creases and mucosa. Aldosterone deficiency causes hyponatremia, hyperkalemia, and orthostatic hypotension, all present in this patient, and the low cortisol with inappropriately high ACTH confirms a primary adrenal cause.

• A. Secondary adrenal insufficiency from pituitary disease would show low or inappropriately normal ACTH, and aldosterone secretion is preserved since it is primarily regulated by the renin-angiotensin system, so hyperkalemia and hyperpigmentation would not occur.
• C. Conn syndrome (primary hyperaldosteronism) causes hypertension with hypokalemia, the opposite of this patient's hypotension and hyperkalemia.
• D. SIADH causes hyponatremia but not hyperkalemia, hyperpigmentation, or elevated ACTH.

This patient has an adrenal crisis precipitated by acute gastroenteritis in the setting of known adrenal insufficiency, presenting with hypotension, altered mental status, and hypoglycemia. Immediate treatment requires intravenous hydrocortisone (typically 100 mg bolus) together with aggressive isotonic fluid resuscitation using normal saline to correct hypovolemia and hyponatremia. Oral therapy is inadequate in this emergency because of impaired gastrointestinal absorption from vomiting and diarrhea and the need for rapid, reliable cortisol replacement.

• B. Dextrose alone corrects hypoglycemia but does not address the underlying cortisol deficiency or hypotension, and oral prednisolone is inadequate in this emergency.
• C. Oral therapy is unreliable in a vomiting, hemodynamically unstable patient and does not provide rapid enough cortisol replacement for a crisis.
• D. Fludrocortisone has a slow onset and is not the primary treatment for acute adrenal crisis; intravenous hydrocortisone provides both glucocorticoid and sufficient mineralocorticoid activity at stress doses.

Resistant hypertension with unprovoked or diuretic-induced hypokalemia is a classic clinical clue to primary hyperaldosteronism, and the plasma aldosterone-to-renin ratio is the recommended initial screening test. An elevated ratio with a suppressed renin suggests autonomous aldosterone production, prompting confirmatory testing such as a saline infusion or oral sodium loading test. Adrenal venous sampling is used later to distinguish unilateral from bilateral disease once the diagnosis is biochemically confirmed and imaging is planned. Antihypertensives that affect the renin-aldosterone axis (like spironolactone) should ideally be withdrawn before testing when feasible.

• A. Adrenal venous sampling is a localization test used after biochemical confirmation, not for initial screening.
• C. The captopril challenge test is not a standard screening step for primary hyperaldosteronism.
• D. This test screens for Cushing syndrome, not hyperaldosteronism.

Paroxysmal headache, palpitations, diaphoresis, and hypertension with an adrenal incidentaloma strongly suggest pheochromocytoma, and plasma free metanephrines or 24-hour urinary fractionated metanephrines are the most sensitive biochemical tests for this diagnosis. These tests reflect continuous intratumoral catecholamine metabolism rather than relying on episodic catecholamine release, which improves sensitivity compared to measuring catecholamines directly. A positive result should prompt cross-sectional imaging and localization (if not already done) followed by preoperative alpha-blockade. Chromogranin A and VMA have lower sensitivity and are not recommended as first-line tests.

• A. Chromogranin A alone has lower sensitivity and specificity than fractionated metanephrines.
• C. Urinary VMA has largely been replaced by fractionated metanephrines due to lower sensitivity.
• D. This test evaluates for Cushing syndrome, not catecholamine-secreting tumors.

Preoperative alpha-blockade (commonly with phenoxybenzamine or a selective alpha-1 blocker) must be initiated before any beta-blockade in patients with pheochromocytoma to prevent unopposed alpha-adrenergic vasoconstriction. If a beta-blocker is given first, blockade of vasodilatory beta-2 receptors while alpha-mediated vasoconstriction remains unopposed can precipitate a hypertensive crisis and acute heart failure. After adequate alpha-blockade is established over 10-14 days, a beta-blocker can be added if needed to control reflex tachycardia. Adequate alpha-blockade and volume expansion reduce the risk of intraoperative hemodynamic instability during tumor manipulation.

• B. Starting beta-blockade before alpha-blockade can precipitate a hypertensive crisis from unopposed alpha-adrenergic stimulation.
• C. Calcium channel blockers may be used as adjuncts but are not the standard first-line preoperative agent; alpha-blockade is required first.
• D. ACE inhibitors are not first-line preoperative therapy for pheochromocytoma.

Elevated serum calcium with an inappropriately high (non-suppressed) parathyroid hormone level and low serum phosphate is the characteristic biochemical pattern of primary hyperparathyroidism. PTH increases renal phosphate excretion, explaining the hypophosphatemia, while it simultaneously increases bone resorption and renal calcium reabsorption, raising serum calcium. Vitamin D deficiency typically causes low or low-normal calcium with secondary elevation of PTH, not hypercalcemia. A 24-hour urinary calcium-to-creatinine clearance ratio can help exclude familial hypocalciuric hypercalcemia, which also shows elevated calcium and PTH but with low urinary calcium excretion.

• A. Familial hypocalciuric hypercalcemia typically shows low urinary calcium excretion and is far less common; it is not suggested by the data given.
• B. Secondary hyperparathyroidism from CKD causes hypocalcemia with elevated phosphate, the opposite of the pattern described, and renal function is normal here.
• D. Vitamin D deficiency causes hypocalcemia or low-normal calcium, not hypercalcemia, and vitamin D levels here are normal.

Hypercalcemia with a suppressed (low) intact PTH level in a patient with a known malignancy, particularly squamous cell lung cancer, points to humoral hypercalcemia of malignancy mediated by tumor secretion of parathyroid hormone-related peptide (PTHrP). PTHrP mimics PTH action on bone and kidney, raising calcium and lowering phosphate, but it suppresses endogenous PTH through negative feedback on the parathyroid glands via the elevated calcium. In primary hyperparathyroidism, PTH itself would be elevated or inappropriately normal, not suppressed. Confirmatory testing can include a PTHrP assay, and treatment targets both the hypercalcemia and the underlying malignancy.

• A. Granulomatous disease-related hypercalcemia raises 1,25-dihydroxyvitamin D but is less likely given the strong malignancy history and does not fit the typical lung cancer pattern as well as PTHrP.
• C. Parathyroid carcinoma would also present with an elevated PTH level, not a suppressed one.
• D. In an autonomous parathyroid adenoma, PTH would be elevated or inappropriately normal, not suppressed, as seen here.

Severe symptomatic hypercalcemia (calcium above 3.5 mmol/L) is a medical emergency best treated initially with aggressive isotonic saline hydration to correct volume depletion and improve renal calcium clearance, followed by an IV bisphosphonate such as zoledronic acid for sustained lowering of calcium. Bisphosphonates inhibit osteoclast-mediated bone resorption and typically begin lowering calcium within 24-48 hours, with maximal effect by 4-7 days, so saline is used as the immediate bridge. Loop diuretics are reserved for patients with volume overload after rehydration and are not first-line therapy, as they can worsen volume depletion. Denosumab is an alternative in bisphosphonate-refractory cases or renal impairment, not the standard first choice.

• A. Denosumab is typically reserved for bisphosphonate-refractory cases or significant renal impairment, not as the initial sole therapy.
• B. Cinacalcet lowers PTH-driven calcium and is not effective or standard for malignancy-associated hypercalcemia.
• D. Furosemide is not first-line and should only be used cautiously after volume repletion, not as primary therapy.

Hypocalcemia with positive Chvostek and Trousseau signs within days of thyroidectomy is the classic presentation of postsurgical hypoparathyroidism, caused by inadvertent removal, devascularization, or bruising of the parathyroid glands during neck dissection. Low parathyroid hormone leads to reduced calcium reabsorption, reduced intestinal absorption via decreased calcitriol, and increased neuromuscular excitability causing perioral tingling and tetany. Treatment requires oral or IV calcium and active vitamin D (calcitriol), with close monitoring since the deficit can be transient or permanent. This is one of the most important recognized complications of thyroid surgery.

• B. A hematoma causes airway compromise with stridor and neck swelling, not Chvostek/Trousseau signs.
• C. Thyrotoxicosis from gland handling would cause tachycardia and tremor, not hypocalcemia or tetany signs.
• D. Recurrent laryngeal nerve injury causes hoarseness or stridor, not hypocalcemic tetany.

Serum 25-hydroxyvitamin D is the storage form with the longest half-life and is the standard test for diagnosing vitamin D deficiency, as recommended by the Endocrine Society and MOH guidelines. Limited sun exposure from covering clothing and staying indoors is a major risk factor for deficiency in Saudi women, producing osteomalacia with bone pain, proximal myopathy, and biochemical findings of low-normal calcium, low phosphate, and raised alkaline phosphatase from secondary hyperparathyroidism. 1,25-dihydroxyvitamin D is tightly regulated and not reliable for assessing body stores. Treatment is with high-dose oral cholecalciferol followed by maintenance dosing.

• A. PTH will be secondarily elevated in deficiency but is not specific or diagnostic for vitamin D status itself.
• B. 1,25-dihydroxyvitamin D is tightly regulated by PTH and does not reflect total body vitamin D stores, so it is not the diagnostic test of choice.
• C. Urinary calcium is typically low in vitamin D deficiency but does not confirm the diagnosis as directly as the vitamin D level.

Dual-energy X-ray absorptiometry (DEXA) of the hip and lumbar spine is the gold-standard screening test for osteoporosis in postmenopausal women aged 65 years and older, as recommended by major guidelines including those followed in Saudi practice. A T-score of -2.5 or below at the hip or spine establishes the diagnosis of osteoporosis, while a T-score between -1.0 and -2.5 defines osteopenia; T-scores are calculated against a young healthy adult reference population. DEXA also guides the decision to start pharmacologic therapy such as bisphosphonates. Routine biochemistry and plain radiographs do not have the sensitivity or standardized criteria needed for osteoporosis screening.

• A. Plain radiographs only detect osteoporosis after substantial bone loss or fracture has already occurred and are insensitive for screening.
• B. Quantitative ultrasound is a peripheral screening tool with lower accuracy than DEXA and is not used for formal diagnosis.
• D. Routine biochemistry may be ordered to exclude secondary causes but does not diagnose or screen for osteoporosis.

Bisphosphonates inhibit osteoclast-mediated bone resorption by binding hydroxyapatite and inducing osteoclast apoptosis, which suppresses bone turnover. Suppressed remodeling impairs the jaw's ability to heal after dental extractions or invasive procedures, predisposing to osteonecrosis of the jaw, a recognized complication particularly with long-term use and invasive dental work. Patients should ideally have dental procedures completed before starting bisphosphonate therapy, and non-urgent extractions should be deferred or carefully planned with the dentist and prescriber. Atypical femoral fractures are another known long-term complication but are not directly relevant to a dental procedure.

• B. Avascular necrosis of the femoral head is not a recognized bisphosphonate complication and is unrelated to dental procedures.
• C. Bisphosphonates lower calcium by suppressing bone resorption; they do not cause hypercalcemia.
• D. Interstitial nephritis is not a characteristic bisphosphonate complication; IV bisphosphonates are associated with acute tubular injury, not this scenario.

This patient meets the Rotterdam criteria for polycystic ovary syndrome, which requires two of three features: oligo-ovulation or anovulation (cycles longer than 35 days), clinical or biochemical hyperandrogenism (hirsutism with Ferriman-Gallwey score greater than 8), and polycystic ovarian morphology on ultrasound (12 or more follicles measuring 2-9 mm or increased ovarian volume), after excluding other causes. Her normal prolactin, TSH, and 17-hydroxyprogesterone exclude hyperprolactinemia, thyroid dysfunction, and non-classic congenital adrenal hyperplasia respectively. PCOS is the most common cause of hyperandrogenic chronic anovulation and is associated with insulin resistance and increased metabolic risk.

• A. An androgen-secreting tumor typically causes rapidly progressive virilization with very high testosterone, not a gradual, mild presentation like this.
• C. Hypothalamic amenorrhea causes low gonadotropins and estrogen without hyperandrogenism or polycystic ovaries.
• D. Congenital adrenal hyperplasia is excluded by the normal 17-hydroxyprogesterone level.

Metabolic syndrome is diagnosed when three or more of the following are present: elevated waist circumference (greater than 102 cm in men), elevated blood pressure (130/85 mmHg or higher, or on treatment), elevated fasting glucose (5.6 mmol/L or higher), elevated triglycerides (1.7 mmol/L or higher), and reduced HDL (less than 1.0 mmol/L in men). This patient has all five components abnormal, clearly meeting the diagnosis. Metabolic syndrome reflects underlying insulin resistance and is associated with a significantly increased risk of type 2 diabetes and cardiovascular disease, independent of LDL cholesterol level, which is not part of the diagnostic criteria.

• A. He has five abnormal components, not two, easily exceeding the required threshold of three.
• B. A diabetic glucose threshold is not required; an impaired fasting glucose of 5.6 mmol/L or higher already satisfies this criterion.
• C. LDL cholesterol is not one of the five diagnostic criteria for metabolic syndrome.

This patient's triad of primary hyperparathyroidism, a pancreatic neuroendocrine tumor (gastrinoma), and a pituitary adenoma (prolactinoma) is classic for multiple endocrine neoplasia type 1 (MEN1), caused by inactivating mutations in the MEN1 tumor suppressor gene, which encodes menin and normally regulates cell proliferation. In contrast, MEN2 results from activating mutations in the RET proto-oncogene and classically presents with medullary thyroid carcinoma, pheochromocytoma, and, in MEN2A, primary hyperparathyroidism, but without pituitary or pancreatic islet tumors. Distinguishing the tumor pattern (parathyroid-pancreas-pituitary for MEN1 versus medullary thyroid-adrenal for MEN2) is key to directing genetic testing and family screening.

• A. PTEN mutations cause Cowden syndrome, associated with hamartomas and breast/thyroid cancer, not this endocrine tumor pattern.
• B. RET mutations cause MEN2, which features medullary thyroid carcinoma and pheochromocytoma, not pancreatic or pituitary tumors.
• D. VHL mutations cause von Hippel-Lindau disease with hemangioblastomas, renal cell carcinoma, and pheochromocytoma, not this tumor triad.

Patients have the right to full disclosure of all clinically significant findings from investigations performed on them, and incidental adrenal masses require prompt evaluation for hormonal activity (catecholamines, cortisol, aldosterone as indicated) and malignant potential based on size and imaging characteristics, following guidelines for adrenal incidentaloma management. Withholding the information, even with good intentions to reduce stress, violates the principle of patient autonomy and the physician's duty of honesty, and could delay diagnosis of a functioning or malignant tumor. Family-first disclosure without the patient's consent breaches confidentiality and autonomy in a competent adult. Timely, transparent communication paired with a clear management plan respects the patient's right to make informed decisions about his own health.

• A. Delaying disclosure to reduce anxiety violates the principle of honesty and could delay necessary workup for a potentially functioning or malignant lesion.
• C. Disclosing to family before the competent patient himself breaches confidentiality and bypasses his right to receive his own medical information first.
• D. Failing to inform a competent patient about a significant finding violates his autonomy and right to know his own health information.